Bayer logo
US MEDICAL AFFAIRS

Publications

Publications

Home/Publications

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated August 25, 2025.

Types of Enhancements Available

Audio Icon
Audio
Infographic Icon
Infographic
Plain language summary icon
Plain Language Summary
Video icon
Video
Digital enhancements icon
Other

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 319    

Filtered results: 319

Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study

López Muñoz AM, et al. Clin Transl Oncol. 2024;11:1-9.

López Muñoz AM,
READ
EMAIL

Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence

Cervantes A, et al. Future Oncol. 2024:1-4.

Cervantes A,
READ
EMAIL

Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).

Chisholm J, et al. Cancers. 2024;16(5):998.

Chisholm J,
READ
EMAIL

Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.

Sugawara T, et al. Mol Oncol. 2024;18(3):726-742.

Sugawara T,
READ
EMAIL

Comprehensive molecular characterization of response to combination immunotherapy in microsatellite stable/mismatch repair-proficient metastatic Colorectal Cancer

Takei S, et al. J Immunother Cancer. 2024;12(2):e008210.

Takei S,
READ
EMAIL

Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer

Anido-Herranz U, et al. Front Oncol. 2024; 14: 1385466.

Anido-Herranz U,
READ
EMAIL

Within-trial healthcare resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS

Morgans AK, et al. J Manag Care Spec Pharm 2024;30(9):991-1000.

Morgans AK,
READ
EMAIL

Use of FOLFOXIRI Plus Bevacizumab and Subsequent Therapies in Metastatic Colorectal Cancer: An Age-Stratified Analysis.

Vassilev ZP, et al. Clin Colorectal Cancer. 2024;23(3):258-271.e1.

Vassilev ZP,
READ
EMAIL

Real World Evaluation of Access-Driven Canadian Treatment Sequences in Progressive Prostate Cancer (REACTIVATE)

Ko JJ, et al. Can Urol Assoc J. 2024;18(7)E194-E203.

Ko JJ,
READ
EMAIL

Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland

Zhang W, et al. Oncotarget. 2024;15: 106-116.

Zhang W,
READ
EMAIL
Bayer logo

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

 

© 2025 Bayer. Bayer and the Bayer Cross are registered trademarks of Bayer.

Site last updated 08/2025

Follow Us

Twitter (X) icon Twitter (X) icon
YouTube icon YouTube icon
LinkedIn icon LinkedIn icon
US Medical Affairs QR Code